Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENDO INTERNATIONAL PLC

(ENDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo International : Presents New XIAFLEX (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting

10/25/2021 | 07:27am EST

DUBLIN - Endo International plc (NASDAQ: ENDP) announced that new post-hoc data from two Phase 3 studies of XIAFLEX (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting.

'The data analysis discusses the importance of patient adherence when treating PD with XIAFLEX,' said Dr. Matthew J. Ziegelmann, urologist and the presenting author.

'Collagenase Clostridium Histolyticum Treatment for Peyronie's Disease: Analysis of Outcomes and Cumulative Benefits After Each Injection Cycle' was submitted by authors Matthew Ziegelmann, M.D.; Genzhou Liu, Ph.D.; Michael P. McLane, Ph.D.; Yiqun Hu, M.D., Ph.D.; and Landon Trost, M.D.

The SMSNA Annual Fall Scientific Meeting is taking place in Scottsdale, Arizona, October 21-24, 2021.

About the Data

A post-hoc analysis of pooled data from two randomized, double-blind, placebo-controlled studies Phase 3 trials was conducted to evaluate incremental changes in penile curvature over the course of CCH treatment in men with PD. The analysis included men who received at least one injection of study medication.1 XIAFLEX is an FDA-approved treatment for adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

Changes from baseline and from the previous penile curvature measurement were calculated after each of the four treatment cycles (weeks 6, 12, 18 and 24). CCH injections were administered in up to four treatment cycles at 6-week intervals; each cycle included two injections 1-3 days apart. For all patients, treatment included penile plaque modeling.1

Data support that incremental benefits were obtained from each of the four CCH treatment cycles administered to men with PD. Results may suggest incremental benefits with performing a full series of four CCH injections and penile modeling, even among men who were initially considered non-responders (achieved

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ENDO INTERNATIONAL PLC
11/22Endo's Qwo« (collagenase clostridium histolyticum-aaes) Data Presented at the American ..
AQ
11/22Endo International plc Announces its Qwo (Collagenase Clostridium Histolyticum-Aaes) Da..
CI
11/18Endo International Unit Start Shipment Of Generic Calcitonin Salmon Injection
MT
11/18Endo Begins Shipment of Generic MIACALCIN« (calcitonin salmon) Injection
PR
11/18Endo Begins Shipment of Generic MIACALCIN? (calcitonin salmon) Injection
CI
11/17Endo International Unit to Help US Government Produce Critical Medicines
MT
11/17Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Prod..
AQ
11/09Oklahoma Supreme Court Throws Out $465 Million Opioid Lawsuit Against Johnson & Johnson
MT
11/09Endo Announces Agreement with Premier to Supply VASOSTRICT (vasopressin injection, USP)..
AQ
11/08Endo International Strikes Deal to Supply Vasostrict Vials Through Premier Program; Sha..
MT
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations
Financials (USD)
Sales 2021 2 933 M - -
Net income 2021 10,2 M - -
Net Debt 2021 6 712 M - -
P/E ratio 2021 4,22x
Yield 2021 -
Capitalization 1 362 M 1 362 M -
EV / Sales 2021 2,75x
EV / Sales 2022 2,77x
Nbr of Employees 3 397
Free-Float 98,4%
Chart ENDO INTERNATIONAL PLC
Duration : Period :
Endo International plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENDO INTERNATIONAL PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 5,83 $
Average target price 6,86 $
Spread / Average Target 17,6%
EPS Revisions
Managers and Directors
Blaise A Coleman President, Chief Executive Officer & Director
Mark Bradley Chief Financial Officer & Executive Vice President
Mark G. Barberio Chairman
Ruth Thorpe Chief Information Officer
Robert Polke Global Head-Operations